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aAbbreviations:   CPT-­1,   carnitine   palmitoyltransferase-­1;;   DIC,   diisopropylcarbodiimide;;   DIEA,  
diisopropylethylamine;;   EDC,   1-­ethyl-­3-­(3-­dimethylaminopropyl)carbodiimide;;   EGCG,   (-­)-­
epigallocatechin-­3-­gallate;;   FASN,   fatty   acid   synthase;;   FBS,   fetal   bovine   serum;;   HOBt,   1-­
hydroxybenzotriazole;;   i.p.,   intraperitoneal;;   MTT,   3-­(4,5-­dimethyl-­1,3-­thiazol-­2-­yl)-­2,5-­diphenyl-­2H-­
tetrazol-­3-­ium   bromide;;   PARP,   poly(ADP-­ribose)   polymerase;;   PBS,   phosphate   buffered   solution;;   PS,  
polymer   supported;;   SDS,   sodium   dodecylsulphate;;   SEM,   standard   error   of   the   mean;;   TBS-­T,   Tris-­
buffered  solution  with  0.05%  Tween  20;;  TEA,  triethylamine.  
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ABSTRACT.  Fatty  acid  synthase  (FASN)  is  a  lipogenic  enzyme  that  is  highly  expressed  in  different  
human  cancers.  Here  we  report  the  development  of  a  new  series  of  polyphenolic  compounds  5-­30  that  
have  been  evaluated  for   their  cytotoxic  capacity   in  SK-­Br3  cells,  a  human  breast  cancer  cell   line  with  
high   FASN   expression.   The   compounds   with   an   IC50   <   50   M   have   been   tested   for   their   ability   to  
inhibit   FASN   activity.   Among   them,   derivative   30   blocks   the   90%   of   FASN   activity   at   low  
concentration  (4   M),  is  highly  cytotoxic  in  a  broad  panel  of  tumor  cells,  induces  apoptosis,  and  blocks  
the   activation   of   HER2,   AKT   and   ERK   pathways.   Remarkably,   30   does   not   activate   carnitine  
palmitoyltransferase-­1  (CPT-­1)  nor  induces  in  mice  weight  loss,  which  are  the  main  drawbacks  of  other  
previously  described  FASN  inhibitors.  Thus,  FASN  inhibitor  30  may  aid  the  validation  of  this  enzyme  
as  a  therapeutic  target  for  the  treatment  of  cancer.    
  
KEYWORDS.  FASN,  fatty  acid  synthase  inhibitors,  CPT-­1,  carnitine  palmitoyltransferase-­1,  structure-­
affinity  relationship,  polyphenols,  anticancer  activity,  breast  cancer  
Page 3 of 39
ACS Paragon Plus Environment
































































Altered   lipogenesis   is   a   hallmark   of   many   types   of   cancer   and   there   is   evidence   that   links  
overexpression   and   overactivation   of   the   lipogenic   enzymes   that   are   involved   in   de   novo   lipid  
biosynthesis  with   different   human   tumors.1  A  key   step   in   elucidating   the   relationship  between  cancer  
and  lipogenesis  was  the  identification  of  the  oncogenic  antigen-­519  (OA-­519),  a  protein  linked  to  poor  
prognosis  in  breast  cancer  patients,  as  fatty  acid  synthase  (FASNa).2  Since  that  initial  finding,  increased  
FASN  expression  level  has  been  observed  in  a  wide  variety  of  solid  human  tumors,  including  cancers  of  
breast,   prostate,   colon,   lung,   bladder,   ovary,   stomach,   endometrium,   kidney,   skin,   esophagus,   tongue,  
and  soft  tissues.  In  addition,  FASN  overexpression  occurs  early  in  tumor  progression  and  is  associated  
with   the  unfavorable  outcomes  of   the  most  aggressive   tumors.3  Thus,  FASN  has  been  considered  as  a  
metabolic  oncogene.4  In  addition,  FASN  inhibition  induces  apoptosis  selectively  in  human  cancer  cells  
both   in  vitro  and   in  vivo,  with  minimal  effect  on  normal  cells.3  This   fact,  directly   related   to   the  high  
dependence   of   the   cancer   cells   on   de   novo   fatty   acid   synthesis   and   to   the   differential   expression   of  
FASN,  makes  this  enzyme  a  suitable  target  for  cancer  treatment  with  a  potential  good  therapeutic  index.  
Indeed,  pharmacological  inhibitors  of  FASN  that  block  tumor  cell  proliferation,  elicit  tumor  cell  death,  
and   prevent   tumor   growth   in   animal   models   have   been   identified.1,3   These   studies   confirmed   the  
proposed   use   of   FASN   inhibitors   as   novel   antitumor   therapeutics.   The   most   representative   FASN  
inhibitors   are   shown   in   Chart   1.   Cerulenin   [(2R,3S)-­3-­[(4E,7E)-­nona-­4,7-­dienoyl]oxirane-­2-­
carboxamide,   1],   a   metabolite   produced   by   the   fungus   Cephalosporum   caerulens,   was   the   first  
characterized   FASN   inhibitor.5   It   induced   selective   cytotoxicity   in   various   types   of   cancer   cells   and  
showed  promising  effects   in  different  cancer  xenograft  models.  However,   the  presence  of   the  reactive  
epoxide   ring  makes   cerulenin   susceptible   to  other  nonspecific   ring-­opening   reactions,   feature   that  has  
limited  any  potential  clinical  application.1,3,6  To  overcome  this  drawback,  related  analog  C75  (trans-­4-­
carboxy-­5-­octyl-­3-­methylenebutyrolactone,  2,  Chart  1)  was  synthesized.7  As  expected  from  its  capacity  
to   inhibit   FASN   activity,   2   showed   significant   antitumor   effects   on   several   cancer   cell   lines   and  
Page 4 of 39
ACS Paragon Plus Environment































































xenograft   models.3   However,   it   has   been   suggested   that   2   could   be   sensitive   to   the   presence   of  
endogenous  thiols.8  In  addition,  both  1  and  2  induce  a  profound  weight  loss,  which  is  far  from  ideal  for  
cancer   patients   undergoing   chemotherapy.   This   side   effect   is   apparently   due   to   their   activity   in  
increasing  fatty  acid  oxidation  through  direct  activation  of  carnitine  palmitoyltransferase-­1  (CPT-­1).9-­11  
Also,   they   reduce   food   intake   by   blocking   the   production   of   hypothalamic   neuropeptide-­Y.11   These  
effects   clearly   hindered   the   further   clinical   development   of   1   and   2.   In   2004,   orlistat   [(-­)-­
tetrahydrolipstatin,  3,  Chart  1],  marketed  as  anti-­obesity  drug,  was  found  to  inhibit  FASN,12  and  more  
recently,   green   tea   polyphenols,   especially   highly   abundant   catechins   such   as   (-­)-­epigallocatechin   3-­
gallate  (EGCG,  4,  Chart  1),  have  received  much  attention  on  the  grounds  of   their  reported  capacity  to  
block   the   formation  and  development  of   tumors   in  a  variety  of  animal  models.13  Furthermore,  EGCG  
has  been  found  to  inhibit  FASN  and  to  induce  selective  apoptosis  in  human  breast  and  prostate  cancer  
cells14-­16  without  producing  concomitant  weight   loss.17  Unfortunately,   its  effectiveness   in  vivo  is  quite  
limited  due   to   its  high   IC50  value,  poor  oral  bioavailability,   and   low  serum  stability.18   In  our   research  
group,  we  are  involved  in  a  project  aimed  at  the  development  of  new  FASN  inhibitors  devoid  of  CPT-­1  
stimulation   as   side   effect  with   the   objective   of   advancing   towards   the   validation   of   FASN   as   a   new  
therapeutic   target   for   the   treatment   of   cancer.  Based   on   our   promising   preliminary   results  with   some  
structurally   simple   molecules   initially   inspired   on   the   polyphenolic   nature   of   EGCG   that   showed  
significant   in  vitro  and  in  vivo  antitumor  properties,19,20  in  the  present  work  we  report  a  new  series  of  
gallate  derivatives  in  which  the  A  subunit  has  been  modified  (compounds  5-­30,  Chart  1).  Among  them,  
derivative  30   stands   out   as   a   highly   cytotoxic   compound   in   a   broad   panel   of   tumor   cells  of  different  
tissue   origins   (IC50   values   ranging   from  1.4   to  9   M).  Furthermore,   compound  30   almost   completely  
abrogates  FASN  activity  at  a  concentration  of  4   M  in  breast  cancer  SK-­Br3  cells,  induces  apoptosis  of  
tumor  cells,  and  interferes  with  the  mitogen-­activated  protein  kinase  (MAPK)  pathway.  Importantly,  all  
these  sought-­after  effects  occur  without  parallel  CPT-­1  stimulation  or  weight  loss  induction.  Overall,  the  
possibility  of  inhibiting  FASN  without  concomitant  weight  loss  induction  clearly  highlights  the  potential  
of  this  enzyme  as  a  new  target  in  oncology.  Accordingly,  FASN  inhibitors  could  become  a  new  class  of  
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drugs   that   aid   in   the   challenging   endeavor   of   handling   those   types   of   tumors   resistant   to   the   current  
therapies  or  those  lacking  adequate  treatments.  
  
Results  and  Discussion    
Synthesis  of  compounds  5-­30.  In  a  previous  study,  and  initially  inspired  by  the  polyphenolic  nature  
of  EGCG,  we  designed  a  small  series  of  compounds  structurally  simpler   than  this  natural  product  and  
with   a   straightforward   synthetic   accessibility.   Encouraged   by   the   interesting   results,20   in   the   present  
work  we  have  expanded  the  structural  variability  and  we  have  studied  the  influence  of  the  A  subunit  in  
the  cytotoxicity  and  FASN  inhibition  of  compounds  5-­30  (Chart  1).  Anticipating  the  need  of  a  synthetic  
route  that  enabled  us  both  the  quick  generation  of  a  variety  of  compounds  as  well  as  their  synthesis  on  
the  gram-­scale  needed  for  in  vivo  studies,  we  set  up  a  methodology  for  the  esterification  reaction  based  
on   the   use   of   polymer   supported   (PS)   reagents   (Scheme   1,   Method   A).   For   this   purpose,   different  
commercially  available  PS  reagents  were  tested,  including  Mukaiyama  (PS-­Mukaiyama),  dicyclohexyl-­  
and  1-­ethyl-­3-­(3-­dimethylaminopropyl)carbodiimide  (PS-­DCC  and  PS-­EDC,  respectively),  and  a  N, -­
dimethylaminopyridine  surrogate  bound  to  polystyrene  (PS-­DMAP).  However,  all  these  reagents  led  to  
different  and  non-­desired  outcomes,   such  as   the  isolation  of  mixtures  of  esterification  product  and  the  
corresponding  acid  anhydride  (with  PS-­Mukaiyama),  of  the  activated  alcohol  intermediate  (PS-­DMAP),  
or  a  lack  of  reactivity  of  the  protected  gallic  acid  with  the  resin  (PS-­DCC  and  PS-­EDC).  Finally,  positive  
results  were  obtained  with  the  use  of  PS-­1-­hydroxybenzotriazole  (PS-­HOBt).  Thus,  protected  gallic  acid  
55  or  56  was  loaded  on  the  resin  in  the  presence  of  diisopropylcarbodiimide  (DIC)  and  DMAP,  and  the  
resulting  activated  acid  57  or  58  linked  to  the  resin  was  filtered,  washed  and  dried  (Scheme  1,  Method  
A).   It   is   important   to   note   that   this   intermediate   can   be   stored   at   least   one   month   at   4   ºC,   without  
significant  reactivity  loss.  In  a  second  step,  the  reaction  of  57  or  58  with  the  corresponding  diol  in  the  
presence  of  diisopropylethylamine  (DIEA)  afforded  all  protected  target  esters  except  38,  39,  46,  and  50  
that  could  not  be  obtained  using  this  PS-­based  methodology  possibly  due  to  steric  hindrance.  Therefore,  
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they  were  synthesized  by  classical  condensation  reaction  between  the  corresponding  acyl  chloride  59  or  
6021  and  the  adequate  diol  in  the  presence  of  triethylamine  (TEA)  (Scheme  1,  Method  B).  Final  removal  
of  the  protecting  groups  either  by  catalytic  hydrogenation  (in  the  case  of  benzyl  groups)  or  by  treatment  
with  a  hydrofluoride  acid-­pyridine  (HF·py)  complex  (for  the  TBS-­protected  intermediates)  afforded  the  
desired  final  compounds  5-­30.  In  the  case  of  benzyl  intermediates  43  and  44,  in  which  the  A  subunit  is  
naphthalene,  catalytic  hydrogenation  for  3  to  5  h  gave  naphthalene  compounds  20  and  21,  respectively,  
whereas   exhaustive   hydrogenation   overnight   afforded   tetrahydronaphthalene   analogues   17   and   18,  
respectively.  
The   synthesis   of   the   starting   carboxylic   acid   5522   involved   the   perbenzylation   of   the   commercial  
methyl  gallate  followed  by  saponification  of   the  ester,  whereas  5623  was  obtained  by  reaction  of  gallic  
acid  with   tert-­butyldimethylsilyl  chloride  (TBSCl)  and  subsequent  selective  cleavage  of  the  silyl  ester.  
Non-­commercial   intermediate   diols   trans-­   and   cis-­1,2,3,4-­tetrahydronaphthalene-­1,4-­diol,24  
naphthalene-­1,2-­diol,25  methyl  1,4-­dihydroxy-­2-­naphthoate,26  and  naphthalene-­1,8-­diol27  were  obtained  
following  previously  described  procedures.    
Cytotoxicity   in   SK-­Br3   cells.  All   the   new   final   compounds   were   first   screened   for   their   in   vitro  
cytotoxic   activity   against   SK-­Br3   human   breast   cancer   cell   line,   selected   because   of   its   high   FASN  
expression.   The   IC50   values   are   shown   in   Table   1,   where   the   reference   compound   4   has   also   been  
included   for   comparative   purposes.   These   data   have   allowed   us   to   carry   out   a   SAR   study   on   the  
influence  of   the  modifications  of   the  A  subunit   in   the  cytotoxic  capacity  of   the  compounds.  The  main  
conclusions  can  be  summarized  as  follows:  (i)  Most  of  the  final  compounds  are  highly  cytotoxic  in  SK-­
Br3  cells  (IC50  <  50   M),  being  more  potent  than  4  (IC50  =  149     20   M);;  (ii)  in  general,  the  presence  of  
at  least  one  aromatic  ring  in  the  A  subunit  is  required  for  cytotoxicity,  as  suggested  by  derivatives  5-­7,  
inactive  in  SK-­Br3  cells  (IC50  >  150   M);;  (iii)  for  those  compounds  where  the  A  subunit  is  a  phenyl  ring  
(8-­14),  cytotoxicity  increases  as   the  distance  between  the  two  galloyl  moieties  augments.  Thus,  all  the  
compounds  with  a  relative  1,4-­substitution  in  the  phenyl  ring  show  lower  IC50  values  than  analogs  8  and  
9  (with  1,2-­  and  1,3-­substitution,  respectively).  Among  them,  derivative  14  deserves  special  attention  as  
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being  the  most  cytotoxic  one  (IC50  =  8   M);;  (iv)  replacement  of  the  benzene  ring  in  the  A  subunit  for  
different   tetrahydronaphthalenes   (derivatives   15-­18)   did   not   yield   any   significant   improvement   in  
cytotoxicity,   with   compounds   showing   IC50   values   between   22   and   42   M;;   (v)   introduction   of   a  
naphthalene   ring   as   A   subunit   (compounds   19-­29)   yielded   some   interesting   derivatives   with   good  
cytotoxicity  values.  Among  them,  polyphenols  20,  23,  28  and  29  with  IC50  values  between  5  and  26   M,  
deserve   special   attention.   Importantly,   this   naphthalene   series   suggests   that,   as   observed   for   benzene  
derivatives  8-­14,  cytotoxicity  increases  as  the  distance  between  the  galloyl  moieties  augments,  being  28  
the  most  potent  compound  (relative  2,6-­orientation  of  galloyl  groups  and  IC50  =  5   M),  and  compounds  
19,  26   and  27   the   less   active   ones   (relative   1,2-­,   1,8-­   and   2,3-­orientation   of   galloyl   groups,   and   IC50  
values  of  74,  78  and  76   M,  respectively).  These  data  prompted  us  to  introduce  a  biphenyl  system  as  A  
subunit  with  the  two  galloyl  groups  as  distant  as  possible  (i.e.  in  a  relative   -­position,  see  Table  1).  
This  modification  led  to  the  identification  of  analog  30,  the  most  potent  derivative  in  the  series  in  terms  
of  cytotoxicity,  with  an  IC50  value  of  4   M.          
FASN   inhibition.   Considering   our   objective   of   identifying   FASN   inhibitors   with   antitumor  
properties,   those  compounds  that   inhibited  more  effectively   the  proliferation  of  the  SK-­Br3  cells  (IC50  
value  lower  than  50   M)  were  assessed  for  their  capacity  to  block  FASN  activity.  Towards  this  end,  SK-­
Br3   cells   were   incubated   for   24   h   in   the   presence   of   a   concentration   of   the   compound   equal   to   its  
cytotoxic  IC50  value  in   these  cells,  and  FASN  activity  was  measured  in  particle-­free  supernatants.  The  
inhibition   is   expressed   as   the   percentage   of   inactivation   compared   to   a   100%  activity   control   sample  
(Table  1).  The  obtained  results  show  that  some  of  the  cytotoxic  compounds  (13,  16,  20,  21,  23,  27  and  
30)  are  indeed  FASN  inhibitors  able  to  block  between  the  30%  and  the  90%  of  its  total  activity.  Among  
them,  derivatives  20  and  30  stand  out  as  being  not  only  highly  cytotoxic  in  SK-­Br3  cells  (IC50  values  of  
21  and  4   M,  respectively)  but  also  the  most  potent  FASN  inhibitors  identified  within  the  series  (90%  of  
FASN   inhibition,   Table   1).   Prompted   by   these   results,   we   previously   disclosed   the   pharmacological  
profile  of  derivative  20,  which  turned  out  to  induce  apoptosis  in  SK-­Br3  cells  without  affecting  CPT-­1  
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activity.20  Considering  that  both  20  and  30  block  FASN  activity  in  a  similar  extent  (up  to  90%)  but  30  
does  it  at  a  five-­fold  lower  concentration  (21   M  for  20  vs  4   M  for  30),  this  latter  compound  is  clearly  
worthy  of  an  in-­depth  pharmacological  study  since  it  could  be  a  good  tool-­compound  for  ensuing  in  vivo  
studies   and  validation  of  FASN  as   a   target  with   therapeutic   interest.  Among   the  obtained   results   it   is  
important  to  note  that  compound  28  had  a  cytotoxic  potency  in  SK-­Br3  cells  comparable  to  compound  
30  but  did  not  inhibit  FASN  significantly  (Table  1),  which  suggests  that  there  are  additional  mechanisms  
apart   from   inhibition   of   FASN   activity   that  may   derive   in   cytotoxic   effects.   Conversely,   an   effect   of  
derivative  30  on  an  additional  target  different  from  FASN  cannot  be  ruled  out.  Accordingly,  we  sought  
to   rule  out  general   cytotoxicity  of   compound  30   and   to  confirm   that  FASN  was   the  main  mechanism  
mediating   the   cell   death   induced   by   this   derivative.   With   respect   to   the   former,   we   determined   the  
capacity  of  compound  30  to  inhibit  cell  proliferation  in  non  cancer  human  mammary  epithelial  HMEpC  
and  hepatic  HL-­7702  cells.  In  both  cell  lines,  derivative  30  induced  little  cytotoxicity,  with  IC50  values  
from  eight  to  ten-­fold  higher  than  in  SK-­Br3  cells  [IC50  (30,  SK-­Br3)  =  4   M;;  IC50  (30,  HMEpC)  =  31  
M;;  IC50  (30,  HL-­7702)  =  41   M].  To  study  the  actual  contribution  of  FASN  to  the  cytotoxic  effects,  its  
expression  was  knocked  down  in  SK-­Br3  cells  using  a  FASN  specific  siRNA  and  cellular  viability  was  
determined  in  parallel  for  transfected  and  non-­transfected  cells.  Our  results  show  that  decreasing  FASN  
expression   in   an   80%   (quantified   by   western   blot   band   intensity   densitometry)   eliminates   the  
cytotoxicity  of  compound  30,  which  does  not  induce  any  significant  cell  death  up  to  a  concentration  of  
10  µM   (Figure   1).  Hence,   derivative  30  was   selected   for   a   comprehensive  biological   characterization  
including  the  study  of  its  cytotoxicity  in  a  panel  of  different  tumor  cell  lines,  its  molecular  mechanism  of  
action  as  well  as  its  selectivity  vs  CPT-­1  enzyme.  
Cytotoxicity  of  FASN  inhibitor  30  in  a  panel  of  tumor  cells.  The  capacity  of  derivative  30  to  induce  
cytotoxicity   was   further   evaluated   in   a   panel   comprising   a   variety   of   tumor   cells   of   different   tissue  
origins,  including  colon,  pancreas,  skin,  liver,  ovary,  breast,  and  lung.  The  IC50  values  obtained  for  the  
different  cell  lines  are  shown  in  Table  2.  In  general,  compound  30  showed  a  remarkable  cytotoxicity  in  
the  tumor  cell  line  panel,  being  especially  relevant  its  potency  in  the  HCT116,  PANC-­1,  A431,  SKOV3,  
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MCF-­7,   ZR-­75-­1,   MDA-­MB-­231,   and   H460   cells   in   which   the   IC50   values   were   below   10   M.   In  
general,  breast  cancer  cells  with  high  FASN  levels,  such  as  SK-­Br3,  MCF-­7,  ZR-­75-­1,  and  MDA-­MB-­
231  cells  (Figure  2A),  are  more  sensitive  to  compound  30,  with  IC50  values  between  2  and  5  µM  (Table  
2).  Lower  FASN  levels  decrease  the  sensitivity  of  cells  towards  compound  30,  as  observed  in  BT-­20  and  
AU565  breast  cancer  cell  lines  (IC50  values  of  17  and  24  µM,  respectively,  Table  2  and  Figure  2A).  This  
correlation  between  FASN  levels  and  cytotoxicity  of  derivative  30  is  also  observed  in  the  hepatic  cancer  
cells  Bel-­7402,  SK-­Hep1  and  HepG2  (Figure  2B)  with   IC50  values  of  40,  56  and  70  µM,  respectively  
(Table  2).  Taken  together,  these  results  clearly  support  the  potential  of  the  new  FASN  inhibitor  30  as  an  
antitumor  compound  of  wide  application  and  prompted  us  to  gain  insights  on  the  cell  death  mechanism  
and  molecular  pathways  involved  in  this  effect.      
  Cell  death  mechanism  and   signaling  pathways.   In  order   to  establish   the  mechanism  of  action  of  
compound  30,  we  first  evaluated  whether  it  induced  apoptosis  and  caspase  activity  by  western  blotting  
analysis  showing  cleavage  of  poly(ADP-­ribose)  polymerase  (PARP).  Treatment  of  SK-­Br3  cells  for  48  h  
induced   a   marked   increase   in   the   levels   of   the   PARP   cleavage   product   (89   kDa   band)   in   a   time-­
dependent  manner  (Figure  3A).  In  the  light  of  the  previously  reported  effect  of  FASN  inhibitors  not  only  
in  apoptosis  but  also  in  the  HER2  receptor  and  its  associated  pathways,17,20,28  we  assessed  the  effects  of  
30   on   HER2   activation   as   well   as   on   its   downstream   signal   transduction   pathways   ERK1/2   and  
PI3K/AKT.  Incubation  of  cells  with  30  dramatically  decreased  the  levels  of  the  phosphorylated  form  of  
HER2  (p-­HER2),  that  occurred  as  soon  as  2  h  after  treatment  (data  not  shown),  and  became  complete  at  
6  h  after  treatment  (Figure  3B).  During  this  period,  there  was  no  significant  change  in  the  total  level  of  
HER2  protein,  as  assessed  by  either  western  blotting  analysis  (Figure  3B)  or  HER2-­specific  ELISA  (data  
not   shown).   Phosphorylated   forms   of   ERK1/2   (p-­ERK1/2)   and   AKT   (p-­AKT)   were   also   noticeably  
decreased   after   6   h   of   exposure   to   compound   30   (Figure   3B).   Overall,   the   derivative   30   induced   a  
sustained  blockade  of  the  HER2  signaling  pathway,  at  least  throughout  the  whole  time  interval  analyzed  
(24  h).  During  this  period,  no  significant  changes  in  the  total  level  of  the  corresponding  proteins  (HER2,  
AKT,   and   ERK1/2)   were   detected.   Remarkably,   under   the   same   culture   conditions,   EGCG   did   not  
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induce  apoptosis  nor  blocked  the  activation  of  HER2  oncogene  and  its  downstream  signal  transduction  
pathways,  ERK1/2  and  PI3K/AKT.20      
CPT-­1  activation  and   in  vivo  weight   loss.  Given   the   importance  of   inhibition  of  FASN  without  a  
cross-­activation  of  CPT-­1,  which  is  relevant  to  avoid  the  side  effect  of  weight  loss,  compound  30  was  
analyzed  both  in  vitro  and  in  mice.  Importantly,  30  did  not  stimulate  CPT-­1  activity  (Figure  4A),   in  a  
similar  manner  to  what  it  had  been  previously  described  for  the  natural  FASN  inhibitor  4  and  in  sharp  
contrast   to   compound   2   which,   as   previously   reported,   produced   a   significant   activation   of   CPT-­1  
activity.  Both  reference  FASN  inhibitors  2  and  4  are   included  in  Figure  4A  for  comparative  purposes.  
Consistently  with  these  in  vitro  results,  healthy  mice  treated  with  a  single  intraperitoneal  (i.p.)  dose  of  
30,   50   or   75   mg/kg   of   compound   30   did   not   show   any   significant   weight   loss   vs   the   control   group  
(Figure  4B).  Food   intake  was  similar   to  controls  and  altered  behavior  or  signs  of  suffering  or  distress  
were   not   observed   in  mice   treated  with   30   (data   not   shown).   These   effects   are   especially   significant  
when  compared  with  animals  treated  with  a  30  mg/kg  i.p.  dose  of  2,  in  which  a  21%  weight  loss,  as  well  
as   signs   of   suffering,   were   observed.   Altogether,   our   findings   indicate   that   the   new   synthetic   FASN  
inhibitor  30  does  not  induce  weight  loss  in  vivo.  
  
Conclusion  
In   this   work   we   report   the   synthesis   of   a   new   series   of   polyphenolic   derivatives   that   have   been  
evaluated  for  their  cytotoxic  capacity  in  SK-­Br3  cells,  a  human  breast  cancer  cell  line  with  high  FASN  
expression.   The   most   cytotoxic   compounds   have   been   further   assessed   as   FASN   inhibitors.   Among  
them,  derivative  30   stands  out  as  a  potent  FASN  inhibitor  which  blocks   the  90%  of  FASN  activity  at  
low   concentration   (4   M)   and   is   highly   cytotoxic   in   a   broad   panel   of   tumor   cells   of   different   tissue  
origins,  with  IC50  values  below  10   M.  At  the  molecular  level,  compound  30  induces  apoptosis  of  tumor  
cells   and   blocks   activation   of   the   HER2   receptor   and   its   downstream   proteins   AKT   and   ERK1/2.  
Importantly,  these  effects  occur  without  parallel  CPT-­1  stimulation  or  in  vivo  weight  loss.  Overall,  our  
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results  clearly  indicate  that  compound  30  is  a  promising  new  FASN  inhibitor  that  could  contribute  to  the  
validation  of  this  enzyme  as  a  therapeutic  target  for  the  treatment  of  different  types  of  cancer.  
  
Experimental  Section  
Chemistry.  Melting  points   (mp,  uncorrected)  were  determined  on  a  Stuart  Scientific  electrothermal  
apparatus.   Infrared   (IR)   spectra  were  measured   on   a  Shimadzu-­8300  or  Bruker  Tensor   27   instrument  
equipped   with   a   Specac   ATR   accessory   of   5200-­650   cm-­1   transmission   range;;   frequencies   ( )   are  
expressed  in  cm-­1.  Nuclear  Magnetic  Resonance  (NMR)  spectra  were  recorded  on  a  Bruker  Avance  300-­
AM  (1H,  300  MHz;;  13C,  75  MHz)  or  Bruker  200-­AC  spectrometer  (1H,  200  MHz;;  13C,  50  MHz)  at  the  
)   are   expressed   in   parts   per   million   relative   to   internal  
tetramethylsilane;;   coupling   constants   (J)   are   in   hertz   (Hz).   The   following   abbreviations   are   used   to  
describe   peak   patterns  when   appropriate:   s   (singlet),   d   (doublet),   t   (triplet),  m   (multiplet),   br   (broad).  
Mass   spectrometry   (MS)   was   carried   out   on   a   Bruker   LC-­Esquire   in   electrospray  mode   (ESI).   High  
Pressure   Liquid   Chromatography-­Mass   Spectrometry   (HPLC-­MS)   analysis   was   performed   using   an  
Agilent  1200LC-­MSD  VL.  LC  separation  was  achieved  with  an  Eclipse  XDB-­C18  column  (5   m,  4.6  
mm  x  150  mm)  together  with  a  guard  column  (5   m,  4.6  mm  x  12.5  mm).  The  gradient  mobile  phases  
consisted   of   A   (95:5  water/MeOH)   and  B   (5:95  water/MeOH)  with   0.1%   ammonium   hydroxide   and  
0.1%  formic  acid  as  the  solvent  modifiers.  MS  analysis  was  performed  with  an  ESI  source.  The  capillary  
voltage  was  set  to  3.0  kV  and  the  fragmentor  voltage  was  set  at  72  eV.  The  drying  gas  temperature  was  
350  ºC,  the  drying  gas  flow  was  10  L/min,  and  the  nebulizer  pressure  was  20  psi.  Spectra  were  acquired  
in  negative  ionization  mode  from  200  to  800  m/z  and  in  UV-­mode  at  four  different  wavelengths  (210,  
230,  254,  and  280  nm).  Satisfactory  HPLC-­MS  traces  confirmed  a  purity  of  at  least  95%  for  all  tested  
compounds  and  their  retention  times  are  provided  on  the  supporting  information.  Hydrogenations  were  
carried   out   in   a   Parr   Hydrogenator   under   an   initial   pressure   of   hydrogen   of   40-­50   psi   at   room  
temperature   for   1   h.  Analytical   thin-­layer   chromatography   (TLC)  was   run   on  Merck   silica   gel   plates  
(Kieselgel  60  F-­254)  with  detection  by  UV  light  (254  nm),  ninhydrin  solution,  or  10%  phosphomolybdic  
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acid  solution  in  ethanol.  Flash  chromatography  was  performed  on  glass  column  using  silica  gel  type  60  
(Merck,   particle   230-­400   mesh)   or   on   a   Varian   971-­FP   flash   purification   system   using   silica   gel  
cartridges   .   Unless   stated   otherwise,   starting   materials,   reagents   and  
solvents  were  purchased  as  high-­grade  commercial  products  from  Sigma-­Aldrich,  Lancaster,  Scharlab  or  
Panreac,  and  were  used  without  further  purification.  Tetrahydrofuran  (THF)  was  distilled  from  sodium  
benzophenone   ketyl   and   used   immediately.   Dichloromethane   (DCM)   was   distilled   from   calcium  
hydride. 
Compounds 55,22 56,23 59,21 and 6021 were synthesized according to described procedures, and their 
spectroscopic data are in agreement with those previously reported. Spectral  characterization  data  of  all  
described  compounds  were  consistent  with  the  proposed  structures.  Satisfactory  HPLC  chromatograms  
were  also  obtained  for  final  compounds  5-­30.  We  include  here  the  data  of  protected  esters  39,  40,  and  
53,   and   final   compounds   16,   17,  23,  29,   and   30.   All   other   compounds   are   fully   characterized   in   the  
Supporting  Information. 
General  procedure  for  the  preparation  of  the  resin-­bound  intermediates  57  and  58.  According  to  
a  previously  optimized  methodology,29  the  following  anhydrous  DCM  solutions  were  sequentially  added  
to  one  equiv  of  PS-­HOBt:  0.6  equiv  of  DMAP  in  20  mL/mmol,  1.5  equiv  of  55  or  56  in  2.5  mL/mmol,  
and   4.4   equiv   of  DIC   in   0.6  mL/mmol.  The   reaction  was   stirred   under   an   argon  atmosphere   at   room  
temperature   for  3  h   and   the   resulting  solid  was   filtered  and  washed  with  DMF,  DCM,  and  THF.  The  
residue  was  dried  under  vacuum  to  give  57  or  58  in  quantitative  yield.  
3,4,5-­Tris(benzyloxy)benzoic  acid  bound  to  PS-­HOBt  (57)  was  prepared  from  475  mg  of  PS-­HOBt,  
39  mg  of  DMAP  dissolved  in  6.4  mL  of  DCM,  350  mg  of  55  dissolved  in  2.0  mL  of  DCM  and  1.2  mL  
of  DMF,  and  0.36  mL  of  DIC  dissolved  in  1.4  mL  DCM.  
3,4,5-­Tris(tert-­butyldimethylsilyloxy)benzoic  acid  bound  to  PS-­HOBt  (58)  was  prepared  from  150  
mg  of  PS-­HOBt,  12  mg  of  DMAP  dissolved   in  2  mL  of  DCM,  128  mg  of  56  dissolved  in  0.6  mL  of  
DCM  and  0.3  mL  of  DMF,  and  0.11  mL  of  DIC  dissolved  in  0.44  mL  DCM.  
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General  procedure  for  the  synthesis  of  protected  esters  31-­37,  40-­45,  47-­49,  and  51-­54  (Method  
A).  A   suspension   of   57   or   58   (2.14   equiv),   the   adequate   diol   (1   equiv)   and   DIEA   (2.86   equiv)   in  
anhydrous   THF   (20   mL/mmol   of   diol)   was   stirred   at   room   temperature   under   an   argon   atmosphere  
overnight.  The  reaction  mixture  was  filtered  through  a  plug  of  silica  gel,  washed  with  saturated  NH4Cl,  
water  and  brine,  dried  over  Na2SO4  and  evaporated  under  vacuum.  The  title  compound  was  obtained  as  a  
white  solid  and  was  used  in  the  following  reaction  without  further  purification.  
1,2-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)ethane   (31)   was   prepared   from   57   and   ethylene   glycol.  
Yield  71%.  
cis-­1,2-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)cyclohexane   (32)   was   prepared   from   57   and   cis-­
cyclohexane-­1,2-­diol.  Yield  64%.  
trans-1,2-Bis([3,4,5-tris(benzyloxy)benzoyl]oxy)cyclohexane (33) was  prepared  from  57  and  trans-­
cyclohexane-­1,2-­diol.  Yield  50%.  
1,2-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)benzene  (34)  was  prepared  from  57  and  cathechol.  Yield  
37%.  
1,3-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)benzene  (35)  was  prepared  from  57  and  resorcinol.  Yield  
68%.  
1,4-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)benzene   (36)   was   prepared   from   57   and   hydroquinone.  
Yield  24%.  
2-­Methyl-­1,4-­bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)benzene   (37)   was   prepared   from   57   and   2-­
methylbenzene-­1,4-­diol.  Yield  52%.  
2-­Methoxy-­1,4-­bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)benzene   (40)   was   prepared   from   57   and   2-­
methoxybenzene-­1,4-­diol.  Yield  30%;;  mp  197-­198   ºC;;   IR  (KBr)     1735,  1585,  1506,  1115;;   1H  NMR  
(200  MHz,  CDCl3)     3.90  (s,  3H,  CH3),  5.24  (s,  4H,  4CH2  Bn),  5.26  (s,  8H,  4CH2  Bn),  6.88-­6.96  (m,  
2H,  benzene),  7.25  (d,  J  =  8.4,  1H,  benzene),  7.34-­7.57  (m,  30H,  Bn),  7.62  (s,  2H,  gal),  7.65  (s,  2H,  gal);;  
13C  NMR  (50  MHz,  CDCl3)     56.1  (CH3),  71.2,  71.3  (4CH2),  75.1  (2CH2),  106.8  (CH),  109.7,  109.8  
(4CH),  113.5,  123.1  (2CH),  124.2  (2C),  127.5,  127.6,  128.0,  128.2,  128.5  (30CH),  136.5,  137.3,  137.4,  
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137.6  (7C),  143.0,  143.1,  149.3,  151.9  (4C),  152.6,  152.7  (4C),  164.1,  164.5  (2C=O);;  ESI-­MS  1007.1 
(M + Na)+. 
cis-1,4-Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]-1,2,3,4-tetrahydronaphthalene (41)  
was  prepared  from  58  and  cis-­1,2,3,4-­tetrahydronaphthalene-­1,4-­diol.  Yield  20%.  
trans-1,4-Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]-1,2,3,4-tetrahydronaphthalene 
(42)  was  prepared  from  58  and  trans-­1,2,3,4-­tetrahydronaphthalene-­1,4-­diol.  Yield  53%.  
1,3-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)naphthalene  (43)  was  prepared  from  57  and  naphthalene-­
1,3-­diol.  Yield  47%.  
1,4-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)naphthalene  (44)  was  prepared  from  57  and  naphthalene-­
1,4-­diol.  Yield  64%.  
1,2-Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]naphthalene (45)  was  prepared  from  58  
and  naphthalene-­1,2-­diol.  Yield  60%.  
1,5-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)naphthalene  (47)  was  prepared  from  57  and  naphthalene-­
1,5-­diol.  Yield  42%.  
1,6-­Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]naphthalene   (48)  was  prepared  from  58  
and  naphthalene-­1,6-­diol.  Yield  24%.  
1,7-­Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]naphthalene   (49)  was  prepared  from  58  
and  naphthalene-­1,7-­diol.  Yield  24%.  
2,3-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)naphthalene  (51)  was  prepared  from  57  and  naphthalene-­
2,3-­diol.  Yield  37%.  
2,6-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)naphthalene  (52)  was  prepared  from  57  and  naphthalene-­
2,6-­diol.  Yield  39%.  
2,7-­Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]naphthalene   (53)  was  prepared  from  58  
and  naphthalene-­2,7-­diol.  Yield  39%;;  mp  66-­67  ºC;;  IR  (neat)   1741,  1578,  1082;;  1H  NMR  (300  MHz,  
CDCl3)     0.19  (s,  12H,  2Me2SiO),  0.29  (s,  24H,  4Me2SiO),  0.99  (s,  36H,  4t-­BuSiO),  1.03  (s,  18H,  2t-­
BuSiO),  7.36  (dd,  J  =  8.9,  2.2,  2H,  naph),  7.42  (s,  4H,  gal),  7.67  (d,  J  =  2.2,  2H,  naph,),  7.92  (d,  J  =  7.9,  
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2H,  naph);;  13C  NMR  (75  MHz,  CDCl3)     -­3.9,  -­3.6  (12CH3),  18.5,  18.8  (6C),  26.1,  26.2  (18CH3),  116.1  
(4CH),  118.4  (2CH),  121.1  (2C),  121.2,  129.1  (4CH),  129.3,  134.4  (2C),  144.0,  148.7  (6C),  149.5  (2C),  
164.8  (2  C=O);;  ESI-­MS  1171.6  (M  +  Na)+. 
-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)-­ -­biphenyl   (54)   was   prepared   from   57   and   1,1'-­
biphenyl-­4,4'-­diol.  Yield  77%.  
General   procedure   for   the   synthesis   of   protected   esters   38,   39,   46,   and   50   (Method   B).  To   a  
solution   of   59   or   60   (2.2   equiv)   and   TEA   (2.2   equiv)   in   anhydrous   THF   (10   mL/mmol),   the  
corresponding  diol  (1  equiv)  dissolved  in  THF  (2  mL/mmol)  was  added.  The  reaction  was  stirred  under  
an  argon  atmosphere  at  room  temperature  overnight.  Afterwards,  the  reaction  mixture  was  washed  with  
saturated  NaHCO3,  dried  over  Na2SO4  and  evaporated  under  reduced  pressure.  The  residue  was  purified  
by  column  chromatography  using  the  appropriate  eluent  to  give  pure  title  compound  as  a  white  solid.  
2,5-­Bis([3,4,5-­tris(benzyloxy)benzoyl]oxy)-­ -­biphenyl   (38)   was   prepared   from   59   and   1,1'-­
biphenyl-­2,5-­diol.  Chromatography  DCM/hexane  7:3  (Rf  0.26);;  yield  57%.  
Methyl 2,5-bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]benzoate (39)  was  prepared  from  
60  and  methyl 2,5-dihydroxybenzoate.  Chromatography  DCM/hexane  2:8  (Rf  0.27,  DCM/hexane  4:6);;  
yield  53%;;  mp  191-­192  ºC;;  IR  (neat)     1741,  1576,  1081;;  1H  NMR  (300  MHz,  CDCl3)     0.18  (s,  12H,  
2Me2SiO),   0.28   (s,   24H,   4Me2SiO),   0.98   (s,   36H,   2t-­BuSiO),   1,02   (s,   18H,   2t-­BuSiO),   3.73   (s,   3H,  
CH3),   7.28   (d,  J  =  8.9,   1H,  benzene),  7.38   (s,   2H,  gal),   7.41   (s,   2H,  gal),   7.45   (dd,  J  =  8,7,   2,9,   1H,  
benzene),  7.89  (d,  J  =  2.8,  1H,  benzene);;  13C  NMR  (75  MHz,  CDCl3)     -­3.5,  -­3.4,  -­3.2  (12CH3),  18.9,  
19.2   (6C),  26.5,  26.6   (18CH3),  52.6   (CH3),  116.5,  116.7   (4CH),  121.1,  121.4   (2C),  124.9   (C),  125.3,  
125.4,   127.4   (3CH),   144.4,   144.6   (2C),   148.6,   148.7   (2C),   149.0,   149.1   (4C),   164.8,   164.9,   165.4  
(3C=O);;  ESI-­MS  (ESI)  1179.6  (M  +  Na)+.  
Methyl 1,4-bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]-2-naphthoate (46)  was  prepared  
from   60   and  methyl 1,4-dihydroxy-2-naphthoate.   Chromatography   DCM/hexane   2:8   (Rf   0.42);;   yield  
41%.  
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1,8-­Bis[(3,4,5-­tris(tert-­butyldimethylsilyloxy)benzoyl)oxy]naphthalene   (50)  was  prepared  from  60  
and  naphthalene-­1,8-­diol.  Chromatography  DCM/hexane  1:1  (Rf  0.24);;  yield  24%.  
General  procedure  for  the  synthesis  of  final  compounds  5-­12,  14,  17,  18,  20,  21,  23,  27,  28,  and  
30.  To  a  solution  of  benzyl  derivative  31-­38,  40,  43,  44,  47,  51,  52,  or  54  in  a  mixture  of  DCM/ethanol  
(270  mL/mmol),  20%  Pd(OH)2  on  carbon  (980  mg/mmol)  was  added,  and  the  mixture  was  hydrogenated  
(initial  hydrogen  pressure:  50  psi)  at  room  temperature  for  3  to  5h  or  overnight  (for  compounds  17  and  
18).   Then,   the   catalyst   was   filtered,   the   solvents   were   evaporated   under   reduced   pressure,   and   the  
resulting  solid  was  recrystallized  from  DCM/methanol,  to  afford  pure  title  compound.  
1,2-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]ethane  (5)  was  prepared  from  intermediate  31.  Yield  95%.  
cis-­1,2-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]cyclohexane  (6)  was  prepared  from  intermediate  32.  Yield  
70%.  
trans-­1,2-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]cyclohexane   (7)   was   prepared   from   intermediate   33.  
Yield  75%.  
1,2-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]benzene  (8) was prepared from intermediate 34. Yield 60%.  
1,3-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]benzene  (9)  was  prepared  from  intermediate  35.  Yield  60%.  
1,4-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]benzene  (10) was prepared from intermediate 36. Yield 80%.  
2-­Methyl-­1,4-­bis[(3,4,5-­trihydroxybenzoyl)oxy]benzene   (11)   was   prepared   from   intermediate   37.  
Yield  67%.  
2,5-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]-­ -­biphenyl  (12) was  prepared  from  intermediate  38.  Yield  
75%.  
2-­Methoxy-­1,4-­bis[(3,4,5-­trihydroxybenzoyl)oxy]benzene  (14) was  prepared  from  intermediate  40.  
Yield  77%.  
1,3-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]-­5,6,7,8-­tetrahydronaphthalene   (17)   was   prepared   from  
intermediate  43.  Yield  92%;;  mp  213  ºC  (dec);;  IR  (neat)     3356,  1705,  1615,  1200;;  1H  NMR  (200  MHz,  
CD3OD)     1.80  (m,  4H,  tetrahydronaph),  2.59  (m,  2H,  tetrahydronaph),  2.83  (m,  2H,  tetrahydronaph),  
6.78  (d,  J  =  2.3,  1H,  tetrahydronaph),  6.84  (d,  J  =  2.3,  1H,  tetrahydronaph),  7.18  (s,  2H,  gal),  7.21  (s,  
Page 17 of 39
ACS Paragon Plus Environment































































2H,  gal);;  13C  NMR  (50  MHz,  CD3OD)   23.6,  23.8,  24.3,  30.6  (4CH2),  110.7  (4CH),  114.4  (CH),  120.4,  
120.6   (2C),   120.8   (CH),   128.4   (C),   140.6,   140.7,   141.1   (3C),   146.7,   146.8   (4C),   150.3,   151.0   (2C),  
166.6,  167.0  (2C=O);;  ESI-­MS  466.9  (M     H) .  
1,4-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]-­5,6,7,8-­tetrahydronaphthalene   (18)   was   prepared   from  
intermediate  44.  Yield  88%.  
1,3-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene  (20)  was  prepared  intermediate  43.  Yield  65%.    
1,4-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (21)  was   prepared   from   intermediate  44.  Yield  
88%.  
1,5-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (23)  was   prepared   from   intermediate  47.  Yield  
30%;;  mp  265  ºC  (dec);;  IR  (KBr)   3404,  1718,  1618,  1209;;  1H  NMR  (300  MHz,  CD3OD)     7.35  (s,  4H,  
gal),  7.40  (d,  J  =  7.5,  2H,  naph),  7.58  (t,  J  =  7.9,  2H,  naph),  7.84  (d,  J  =  8.2,  2H,  naph);;  13C  NMR  (50  
MHz,  DMSO-­d6)     109.2  (4CH),  117.5  (2CH),  119.3  (2C),  127.6,  127.8  (4CH),  128.4  (2C),  139.6  (2C),  
145.8  (2C),  146.7  (4C),  164.5  (2C=O);;  ESI-­MS  462.7  (M     H) .  
2,3-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (27)  was   prepared   from   intermediate  51.  Yield  
60%.  
2,6-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (28)  was   prepared   from   intermediate  52.  Yield  
54%.  
-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]-­ -­biphenyl   (30)   was   prepared   from   intermediate   54.  
Yield  70%;;  mp  268  ºC  (dec);;  IR  (KBr)   3396,  1701,  1608,  1192;;  1H  NMR  (300  MHz,  CD3OD)     7.24  
(s,  4H,  gal),  7.24-­7.28  (m,  4H,  biphenyl),  7.67-­7.71  (m,  4H,  biphenyl);;  13C  NMR  (50  MHz,  CD3OD)     
110.8   (4CH),  120.8   (2C),  123.5,  129.2   (8CH),  139.4   (2C),  140.6   (2C),  146.9   (4C),  152.4  (2C),  167.2  
(2C=O);;  ESI-­MS  488.8  (M     H) .  
General  procedure   for   the  synthesis  of   final  compounds  13,  15,  16,  19,  22,  24-­26,  and  29.  To  a  
solution  of  tert-­butyldimethylsilyl  derivative  39,  41,  42,  45,  46,  48-­50,  and  53  in  a  mixture  of  pyridine  
(5.8  mL/mmol)  and  THF  (11.5  mL/mmol),  HF·py  complex  (5.8  mL/mmol)  was  added,  and  the  reaction  
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was   stirred   at   room   temperature.   After   the   complete   disappearance   of   starting   material   (TLC)   the  
reaction  mixture  was  diluted  with  water  (50  mL/mmol)  and  the  crude  was  extracted  with  ethyl  acetate.  
The  organic  layers  were  then  combined,  washed  with  saturated  aqueous  CuSO4,  dried  over  MgSO4,  and  
concentrated   under   reduced   pressure.   The   obtained   off-­white   solid   was   recrystallized   from  
DCM/methanol,  to  afford  pure  title  compound.  
Methyl   2,5-­bis[(3,4,5-­trihydroxybenzoyl)oxy]benzoate   (13)   was   prepared   from   intermediate   39.  
Yield  70%.  
cis-­1,4-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]-­1,2,3,4-­tetrahydronaphthalene   (15)   was   prepared   from  
intermediate  41.  Yield  88%.  
trans-­1,4-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]-­1,2,3,4-­tetrahydronaphthalene   (16)   was   prepared  
from  intermediate  42.  Yield  62%;;  mp  225  ºC  (dec);;  IR  (neat)     3351,  1683,  1612,  1214;;  1H  NMR  (300  
MHz,  acetone-­d6)     2.09-­2.15  (m,  2H,  tetrahydronaph),  2.43-­2.47  (m,  2H,  tetrahydronaph),  6.23  (s,  2H,  
tetrahydronaph),  7.12  (s,  4H,  gal),  7.37-­7.47  (m,  4H,  tetrahydronaph),  8.07  (br  s,  2H,  OH),  8.20  (br  s,  
4H,  OH);;  13C  NMR  (75  MHz,  acetone-­d6)     25.8  (2CH2),  69.8  (2CH),  109.9  (4CH),  122.0  (2C),  129.6,  
130.5  (4CH),  136.6,  139.9  (4C),  146.1  (4C),  166.2,  167.0  (2C=O);;  ESI-­MS  467.0  (M     H) .  
1,2-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (19)  was   prepared   from   intermediate  45.  Yield  
80%.  
Methyl   1,4-­bis[(3,4,5-­trihydroxybenzoyl)oxy]-­2-­naphthoate   (22)   was   prepared   from   intermediate  
46.  Yield  70%.  
1,6-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (24)  was   prepared   from   intermediate  48.  Yield  
60%.  
1,7-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (25)  was   prepared   from   intermediate  49.  Yield  
69%.  
1,8-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (26)  was   prepared   from   intermediate  50.  Yield  
78%.  
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2,7-­Bis[(3,4,5-­trihydroxybenzoyl)oxy]naphthalene   (29)  was   prepared   from   intermediate  53.  Yield  
55%;;  mp  273  ºC  (dec);;  IR  (KBr)     3389,  1687,  1610,  1146;;  1H  NMR  (300  MHz,  CD3OD)     7.26  (s,  4H,  
gal),  7.35  (dd,  J  =  8.9,  2.1,  2H,  naph),  7.70  (d,  J  =  2.1,  2H,  naph),  7.99  (d,  J  =  8.9,  2H,  naph);;  13C  NMR  
(75  MHz,  CD3OD)     109.6   (4CH),  118.6   (2CH),  119.5   (2C),  121.5,  129.3   (4CH),  129.8,  134.9   (2C),  
139.6,  145.7  (6C),  150.0  (2C),  166.1  (2C=O);;  ESI-­MS  487.0  (M  +  Na)+.  
Biochemistry.   EGCG,   3-­(4,5-­dimethyl-­1,3-­thiazol-­2-­yl)-­2,5-­diphenyl-­2H-­tetrazol-­3-­ium   bromide  
(MTT),  EDTA,  dithiotreitol,  acetyl-­CoA,  malonyl-­CoA,  and  NADPH  were  purchased  from  Sigma  (St.  
Louis,  MO,  USA),   and  2   from  Alexis  Biochemicals   (San  Diego,  CA,  USA).  Monoclonal  anti-­ -­actin  
mouse  antibody  (C-­4),  monoclonal  anti-­FASN,  polyclonal  anti-­ -­actin  and  polyclonal  Her-­2  (Neu-­C18)  
rabbit   antibody   were   from   Santa   Cruz   Biotechnology   (Santa   Cruz,   CA,   USA).   Antibody   against  
phospho-­Her-­2   (C-­erb-­2   Ab18)   was   mouse   monoclonal   from   Thermo   Fisher   (Fremont,   CA,   USA).  
Rabbit   polyclonal   antibodies   against   PARP,   AKT,   phospho-­AKTSer473,   ERK-­1   and   -­2,   and   mouse  
monoclonal  antibodies  against  phospho-­ERK-­1  and  -­2  were  from  Cell  Signaling  Technology  (Denvers,  
MA,  USA).  Peroxidase-­conjugated  secondary  antibodies  were  from  Calbiochem  (San  Diego,  CA,  USA).  
CPT-­1   activity   assay  was   done   using   palmitoyl-­CoA   lithium   salt   from  Sigma   (St.  Louis,  MO,  USA),  
fatty  acid-­free  bovine  serum  albumin  from  Roche  (Manheim,  Germany),  L-­Carnitine  hydrochloride  from  
Sigma  (St.  Louis,  MO,  USA),  and  L-­[methyl-­3H]  carnitine  hydrochloride  (82  Ci/mmol)  from  Amersham  
Biosciences.  
Cell  lines  and  cell  culture.  Cells  were  routinely  incubated  at  37  ºC  with  5%  CO2.  MCF-­7  and  MDA-­
MB-­231   breast   cancer   cells   were   obtained   from   the   American   Type   Culture   Collection   (ATCC,  
Berlin,  Germany)  containing  10%  heat-­inactivated  fetal  bovine  serum  (FBS,  HyClone  Laboratories,  UT,  
USA),  1%  L-­glutamine,  1%  sodium  pyruvate,  50  U/mL  penicillin,  and  50   g/mL  streptomycin  (Gibco).  
SK-­Br3   breast   cancer   cells  were   obtained   from  Eucellbank   (Barcelona,  Spain),   and  were   passaged   in  
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-­glutamine,  1%  sodium  pyruvate,  50  U/mL  penicillin,  
and  50   g/mL  streptomycin.    
Cytotoxicity   assay.   Drug   sensitivity   was   determined   using   a   standard   colorimetric   MTT   assay.  
Briefly,  cells  were  plated  out  at  a  density  of  5  or  7  x  103  cells/100   L/well  in  96-­well  microtitre  plates,  
and   allowed   an   overnight   period   for   attachment.   Then   the   medium   was   removed   and   cells   were  
incubated  for  48  h  with  fresh  medium  containing  different  concentrations  of  EGCG  or  the  corresponding  
compound  5-­30.  Following  treatment,  drug-­free  medium  (100   L/well)  and  10   L  of  a  5  mg/mL  MTT  
solution  were  added  and  cells  were  incubated  for  3  h  at  37  ºC.  After  careful  removal  of  the  supernatants,  
the   MTT-­formazan   crystals   formed   by   metabolically   viable   cells   were   dissolved   in   DMSO   (100  
L/well)  and  absorbance  was  measured  at  570  nm  in  a  multi-­well  plate   reader  (Model  Anthos  Labtec  
2010  1.7)  or  at  540  nm  on  a  FlexStation  3  instrument.  
FASN  activity  assay.  After  6,  12  or  24  h  of  exposure  to  compound  under  study,  cells  were  harvested  
by  treatment  with  trypsin-­EDTA  solution,  pelleted  by  centrifugation,  washed  twice,  and  resuspended  in  
cold  phosphate  buffered  solution  (PBS).  Cells  were  sonicated  during  30  min  at  4  ºC  (PSelecta  Ultrasons)  
and  centrifuged  for  15  min  at  4  ºC  to  obtain  particle-­free  supernatants.  FASN  activity,  expressed  in  nmol  
NADPH  oxidized  min-­1·protein  mg-­1,  was  assessed  in  particle-­free  supernatant  samples  of  equal  protein  
content   (measured  by   the  Lowry-­based  BioRad  assay)  by  spectrophotometrically  monitoring  oxidation  
of  NADPH  at  340  nm  as  described.17  
RNA   interference-­mediated   silencing   of   the   FASN   gene.   FASN   siRNA   (h),   a   pool   of   3   target-­
specific  19-­25  nt  siRNAs,  commercially  available  from  Santa  Cruz  Biotechnology,  was  used  following  
to  knock  down  FASN  gene  expression   in  SK-­Br3  cells.  To  determine  
cytotoxicity  in  these  cells,  the  MTT  protocol  indicated  above  was  followed  except  for  the  fact  that  the  
percentage  of  cell  viability  was  measured  after  24  h  incubation  in  the  presence  of  compound  30.  
Immunoblot   analysis   of   p185HER2/neu,   phospho-­p185HER2/neu,   ERK1/2,   phospho-­ERK1/2,   AKT,  
phospho-­AKTSer473  and  PARP.  Following  treatment  of  SK-­Br3  cells  with  EGCG  or  FASN  inhibitor  30  
at  the  corresponding  concentration  and  for  the  indicated  time,  cells  were  harvested  using  trypsin-­EDTA,  
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washed  twice  with  PBS,  and  stored  at  -­80  ºC.  Cells  were  lysed  in  lysis  buffer  (1  mM  EDTA,  150  mM  
NaCl,  100   g/mL  phenylmethylsulfonyl  fluoride  50  mM  Tris-­HCl,  pH  7.5)  and  kept  at  4  ºC  while  they  
were  routinely  mixed  every  2  min  on  the  vortex  during  30  min.  A  sample  was  taken  for  measurement  of  
protein   content   by   the   Lowry-­based  BioRad   assay.   Equal   amounts   of   protein  were   heated   in   sodium  
dodecylsulphate   (SDS)   sample   buffer   (Laemmli)   for   5   min   at   95   ºC,   separated   on   a   3-­8%   SDS-­
polyacrylamide   gel   (p185HER2/neu,   phospho-­p185HER2/neu)   or   4-­12%   SDS-­polyacrylamide   gel   (AKT,  
phospho-­AKT,  ERK1/2,  phospho-­ERK1/2,  and  PARP),  and  transferred  onto  nitrocellulose  membranes.  
Membranes  were  incubated  for  1  h  at  room  temperature  in  blocking  buffer  (2.5%  powdered-­skim  milk  
in   tris-­buffered  solution  with  0.05%  Tween-­20;;  TBS-­T  [10  mM  Tris-­HCl  pH  8.0,  150  mM  NaCl,  and  
0.05%   Tween-­20])   to   prevent   non-­specific   antibody   binding,   and   incubated   with   the   corresponding  
primary  antibody  diluted   in  blocking  buffer  overnight  at  4   ºC.  After  3x5  min  washes   in  TBS-­T,  blots  
were   incubated   for   1   h  with   corresponding   peroxidase   conjugated   secondary   antibody   and   developed  
employing   a   commercial   kit   (West   Pico   chemiluminescent   substrate).   Blots   were   re-­probed   with   an  
antibody  against   -­actin  as  control  of  protein  loading  and  transfer.  
Measurement  of  CPT-­1  activity.  CPT-­1  activity  was  assayed  by  the  forward  exchange  method  using  
L-­[3H]carnitine  as  we  previously  described.10  Briefly,  reactions  (total  volume  of  0.5  mL)  consisted  in  the  
standard   enzyme   assay   mixture   with   200   M   of   the   corresponding   FASN   inhibitor,   2   mM   L-­
[3H]carnitine   (~5000  dpm/nmol),  80   M  palmitoyl-­CoA,  20  mM  HEPES  (pH  7.0),  1%  fatty  acid-­free  
albumin,  and  40-­75  mM  KCl.  Reactions  were  initiated  by  addition  of  isolated  intact  yeast  mitochondria.  
The  reaction  was  linear  up  to  4  min  and  all  incubations  were  done  at  30  ºC  for  3  min.  Reactions  were  
stopped   by   addition   of   6%   perchloric   acid   and   were   then   centrifuged   at   2500   rpm   for   5   min.   The  
resulting   pellet   was   suspended   in   water   and   the   product   [3H]palmitoylcarnitine   was   extracted   with  
butanol   at   low   pH.  After   centrifugation   at   2300   rpm   for   3  min,   an   aliquot   of   the   butanol   phase  was  
transferred  to  a  vial  and  counted  by  liquid  scintillation.  To  perform  the  assay,  mitochondria  from  GS115  
Pichia  pastoris   transformants   that  express  Rat  CTPIA  were   isolated  by  disrupting   the  yeast  cells  with  
glass  beads  as  previously  described.10    
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In vivo experiments. Male mice C57BL/6J (12 weeks, 23-25 g) were purchased from Harlan 
Laboratories (France), fed ad libitum with a standard rodent chow and housed in a light/dark 12 h/12 h 
cycle at 22 ºC for one week. Animals were randomized into four groups (treated with vehicle or 
compounds  2, 4 or 30) of 4 animals each. All experiments were done in accordance with guidelines on 
animal care and use established by University of Barcelona School of Farmacia Institutional Ethic and 
Scientific Committee (Barcelona, Spain). Treatments were done as previously described.11,30 Briefly, 
mice were fasted for 12 h during the dark cycle before treatment. Each group received a single i.p. 
injection (0.5 mL) of FASN inhibitor at the corresponding dose or vehicle alone  (DMSO),  dissolved  in  
RPMI  1640  medium.  After  i.p.  injections,  mice  were  given  free  access  to  rodent  chow  for  24  h.  At  this  
time,  the  experiment  finished  and  body  weight  was  registered.  
Statistical   analysis   for   in   vivo   studies.  Results   -­way  
ANOVA  using  a  Tukey  test  as  a  post-­test.  P<0.05  was  considered  statistically  significant.  All  data  are  
means  ±  SD.  All  observations  were  confirmed  by  at  least  three  independent  experiments.    
  
Supporting  Information  Available.  Spectral  characterization  data  of  protected  esters  31-­38,  41-­52,  
and   54   and   final   compounds   5-­15,  18-­22,  24-­28,   as  well   as  HPLC-­MS  analysis  of  purity   for  all   final  
compounds  5-­30.  This  material  is  available  free  of  charge  via  the  Internet  at  http://pubs.acs.org.  
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>150   N.D.   18  
  
41 3   N.I.  
6c  
  
>150   N.D.   19  
  
74 2   N.D.  
7c  
  
>150   N.D.   20c  
  
21 7   90%  
8c  
  
125 5   N.D.   21c  
  
29.0 0.3   69%  
9c  
  
42 7   N.I.   22  
  
28 6   N.I.  
10c  
  
25 4   N.I.   23  
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23 2   N.I.   24  
  
39 8   N.I.  
12  
Ph   
17 2   N.I.   25  
  




36 7   43%   26  
  
78 4   N.I.  
14  
OMe   
8 1   N.I.   27c  
  
76 9   31%  
15  
  
22 4   N.I.   28  
  
5 1   N.I.  
16  
  
42 5   41%   29  
  
26 10   N.I.  
17  
  
31 3   N.I.   30      4 1   90%  
EGCG  (4)   149 20   18%  
 
aThe   values   are   the   mean SEM   from   two   independent   experiments   performed   in   triplicate.   bFASN  
inhibition   values   are   determined   at   a   concentration   equal   to   the   IC50   value   of   the   cytotoxicity   of   the  
compound   in   SK-­Br3   cells.   cData   are   from   reference   20.   N.D.,   not   determined.  N.I.,   no   significant  
inhibition  of  FASN  activity  at  the  tested  concentration.    
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Cell  line   IC50  ( M)a  
Colon   HCT116   4     2  
Pancreas   PANC-­1   2.1     0.5  
Skin   A431   1.4     0.1  
Liver  
Bel-­7402   40     3  
SK-­Hep1   56     5  
HepG2   70     21  
Ovary   SKOV3   5     2  
Breast  
SK-­Br3   4     1  
MCF-­7   3.8     0.8  
ZR-­75-­1   1.9     0.3  
MDA-­MB-­231   5     3  
BT-­20   17     2  
AU565   24     5  
Lung  
HCC827   14     8  
H460   9     1  
A549   17     10  
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Scheme  1.  Synthesis  of  final  compounds  5-­30.a  
  
  
aReagents  and  conditions:  a)  PS-­HOBt,  DIC,  DMAP,  DCM,  rt,  quantitative;;  b)  (COCl)2,  DMF,  toluene,  
55   ºC,   quantitative;;   c)  DIEA,  THF,   rt,   20-­77%;;   d)  TEA,  THF,   rt,   24-­53%;;   e)  H2,  Pd(OH)2/C,  EtOH,  
DCM  (P  =  Bn),  rt,  54-­95%;;  f)  HF·py,  pyridine,  THF  (P  =  TBS),  rt,  55-­88%.  
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Chart  1.  Reported  FASN  inhibitors  cerulenin  (1),  C75  (2),  orlistat  (3),  and  (-­)-­epigallocatechin  3-­gallate  
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LEGENDS  FOR  FIGURES  
Figure  1.  (A)  Effect  of  siRNA-­induced  silencing  of  FASN  gene  expression  on  cytotoxicity  induced  by  
compound  30.   Cytotoxicity   of   compound  30   at   different   concentrations   (white   bars)   is   eliminated  by  
siRNA-­induced  reduction  of  FASN  expression  levels  (black  bars).  (B)  SK-­Br3  breast  cancer  cells  were  
transfected  with   siRNA-­targeting   FASN   for   72   h.   Equal   amounts   of   total   protein   from   SK-­Br3   cells  
transfected  with  siRNA-­targeting  FASN  or  with  the  control  were  subjected  to  immunoblotting  analyses  
with   antibodies   against   FASN   or   -­actin.   Results   shown   in   panel   A   are   the   average±SEM   of   three  
different  experiments  performed  in  duplicate.  Gels  shown  in  panel  B  are  representative  of  those  obtained  
in  two  independent  experiments.   -­test)  vs  the  same  concentration  of  compound  30  
in  control-­transfected  cells.    
  
Figure  2.  FASN  expression  levels  in  different  breast  (A)  and  liver  (B)  cancer  cell  lines.  Equal  amounts  
of  total  protein  were  subjected  to  immunoblotting  analysis  with  a  monoclonal  antibody  against  FASN.  
Immunoreactive   bands   in   the   figure   are   from   one   representative   experiment.   Equivalent   results  were  
found   in   two   to   four   independent   experiments.   Blots  were   re-­probed  with   an   antibody   for   -­actin   to  
control  for  protein  loading  and  transfer  (not  shown  for  the  sake  of  clarity).    
  
Figure  3.  Compound  30  (A)  induces  apoptosis  as  assessed  by  PARP  cleavage  (note  intact  PARP  at  116  
kDa   and   its   cleavage   product   at   89   kDa);;   and   (B)   blocks   the   activation   of  HER2,  AKT  and  ERK1/2  
signaling  pathways.  SK-­Br3  cells  were  treated  with  30  for  6,  12  or  24  h,  and  equal  amounts  of  lysates  
were   immunoblotted   with   the   corresponding   antibody.   Blots   were   re-­probed   for   -­actin   as   loading  
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Figure  4.  Compound  30  (A)  does  not  modulate  CPT-­1  activity  in  vitro  and  (B)  does  not  induce  weight  
loss  in  vivo  in  a  similar  manner  to  EGCG  (4)  and  in  sharp  contrast  to  2,  both  included  in  the  Figure  for  
comparative   purposes.   CPT-­1   activity   was   determined   in   intact   yeast   mitochondria   as   a   source   of  
enzyme  in  the  absence  or  presence  of   the  corresponding  compound.  For  determination  of  the  effect  of  
the  compounds  in  body  weight,  mice  were  fasted  for  12  h,  treated  with  a  single  i.p.  (30,  50  or  75  mg/kg)  
dose   of   the   compound   under   study   or   vehicle   as   indicated,   refed   for   24   h,   and   body   weight   was  
registered.  Results  shown  are  the  average±SEM  of  a  least  three  different  experiments  with  independent  
mitochondrial  preparations  (panel  A)  or  the  average±SEM,  n=4  (panel  B).          
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FASN inhibitor (90% inhibition at 4 M)
Cytotoxic in a broad panel of human tumor cell lines (IC50 < 10 M)
Induces apoptosis and blocks HER2, ERK1/2 and AKT signaling pathways
No cross-activation of CPT-1 in vitro
No weight loss induction in vivo
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